JAFRON(SZ:300529) Sou Hu Cai Jing·2025-07-29 09:45Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Jianfan Biological Technology Group Co., Ltd, indicating a recent increase in stock price and a low rolling PE ratio compared to the industry average [1][3] - As of March 31, 2025, the number of shareholders for Jianfan Biological has increased to 52,502, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company specializes in the research, production, and sales of biomedical materials and high-tech medical devices, with a range of products including various blood purification devices and disinfectants [2] Group 2 - The latest financial results for the first quarter of 2025 show that Jianfan Biological achieved a revenue of 548 million yuan, representing a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71% from the previous year, with a gross profit margin of 80.74% [2] - The company ranks 52nd in the medical device industry based on its PE ratio of 26.63, while the industry average is 55.46 and the median is 37.74 [1][3] - Jianfan Biological has received multiple accolades, including recognition as a key high-tech enterprise under the National Torch Program and has established various research platforms, demonstrating its commitment to innovation and technology [2]